UPC Case Law
Meril GmbH v Respondent 1 and SWAT Medical AB
Decision of the UPC Court of Appeal of 5 May 2025, UPC CoA 635/2024
UPC Case Law by Pitch, edited by Bart Lieben · Published
TL;DR
The Court of Appeal set aside a Paris Central Division order that had given a European patent attorney and his company access to all pleadings and evidence in a revocation counterclaim. Neither applicant had a validly appointed representative, so access could not be granted. The court also held that costs are normally not awarded in R 262.1(b) RoP access-to-file applications, and that a reasoned decision under R 235.3 RoP is effectively a default decision, so it can be challenged by an application to set aside under R 356.1 RoP.
Key holding
Access to written pleadings and evidence under R 262.1(b) RoP must not be granted to members of the public who are not represented. A respondent who must be represented but files a Statement of response signed by himself has failed to lodge a Statement of response. R 235.3 RoP is a lex specialis (a specific rule that prevails over the general one) for a late Statement of response on appeal. It needs no request, and the resulting reasoned decision is effectively a default decision, so R 356.1 RoP (application to set aside within one month of service) applies mutatis mutandis. Costs are not awarded in R 262.1(b) RoP applications, save for unnecessary costs under Art 69(3) UPCA in exceptional cases.
Questions decided
- Has a Statement of response been lodged if it is signed by a party not allowed to represent himself?
- Can a party barred from self-representation file an R 293 RoP change of representative?
- Does a reasoned decision under R 235.3 RoP require a request, and can it be set aside under R 356.1 RoP?
- Can access under R 262.1(b) RoP be granted to unrepresented members of the public?
- Are costs recoverable in applications for access to pleadings and evidence under R 262.1(b) RoP?
Full summary
Read the full analyses for free — create a free account
With a free Academy account you read the full analysis of every Court of Appeal decision: the facts and procedure, the issues, the court’s reasoning and the practice points. Your name, an e-mail address and a password; no payment, and you can delete the account yourself at any time.
In the same case
- Decision · UPC CoA 464/2024
Meril Italy Srl and others v Edwards Lifesciences Corporation
The Court of Appeal upheld EP 3 646 825 as amended by Auxiliary Request II and confirmed that Meril's Myval Octacor heart valve system infringes it.
- Order · UPC CoA 166/2025
Meril GmbH and others v Edwards Lifesciences Corporation
The Court of Appeal refused Meril's request to suspend the Munich Local Division's infringement decision in favour of Edwards Lifesciences pending Meril's appeal.
- Order · UPC CoA 635/2024
Meril GmbH v SWAT Medical AB and another
A lawyer or European Patent Attorney who is personally a party before the UPC must still be represented by someone else.
- Order · UPC CoA 636/2024
Meril Life Sciences Pvt. Ltd v Respondent 1 and SWAT Medical AB
A lawyer or European Patent Attorney who is a party before the UPC cannot represent himself and must instruct a separate authorised representative.
More on confidentiality and access to the file
- Decision · UPC CoA 163/2026
PAUSTIAN & PARTNER Patentanwälte mbB v NUC Electronics Europe GmbH and others
The Court of Appeal granted a patent law firm access to the statements of appeal and statements of grounds of appeal in three closed appeals concerning EP 2 028 981.
- Order · UPC CoA 133/2026
The Walt Disney Company and others v InterDigital VC Holdings, Inc.
A request under R 262A RoP to stop the other party from accessing or using confidential information cannot be made for the first time on appeal for material already filed at first instance.
- Order · UPC CoA 176/2026
Netflix Services Germany GmbH and others v DivX, LLC
The Court of Appeal refused Netflix's request for suspensive effect against the Munich Local Division's infringement decision in favour of DivX, even though the EPO Opposition Division revoked the patent after that decision.